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June 7, 1990 Abstract Since (3-adrenoceptor antagonists were first introduced in the 1960s (1), they have received major attention. They have been de monstrated to be useful in the management of cardiovascular diseases, including hyperten sion, cardiac arrhythmias and angina pectoris (2).
Because nonselective (3-adrenoceptor  an  tagonists  have some undesirable  effects  through blocking (32-adrenoceptors such as contraction of bronchial smooth muscle and inhibition of glycogenolysis, these drugs are usually not used in patients with bronchial asthma and must be used cautiously in dia betics who are receiving insulin. As a con sequence, drugs that exhibit selectivity for 13, adrenoceptors have been developed. In fact, metoprolol or practolol, cardioselective l3 adrenoceptor antagonists, are less likely to increase airway resistance in asthmatic pa tients than propranolol (3, 4).
Betaxolol is a cardioselective (3-adrenocep tor antagonist devoid of partial agonist ac tivity, with little membrane stabilizing ac tivity (5). Like atenolol, betaxolol exhibited a high (31-adrenoceptor selectivity in isolated tissues (5-7) and had a hypotensive effect in SHR (8). In patients with coronary artery disease, acute intravenous administration of betaxolol did not increase the systemic arte rial resistance at all (9), suggesting that the effect of betaxolol on the total peripheral re sistance is different from those of other ,3 adrenoceptor antagonists (10). Furthermore, administration of betaxolol significantly de creased the myocardial oxygen demand, esti mated from the double product (heart ratex systolic pressure), in patients with ischemic heart disease (1 1). The present study was designed to investigate the effects of be taxolol on cardiohemodynamics and coronary circulation in comparison with those of ate nolol, a cardioselective i3-adrenoceptor an tagonist, and propranolol, a nonselective one.
Materials and Methods

Cardiohemodynamic
profile: Experiments were performed on 21 mongrel dogs of either sex weighing 7-15 kg. The animals were an esthetized initially with 30 mg/kg, i.v., of sodium pentobarbital, followed by an infusion of 4 mg/kg/hr, i.v. Following tracheal intuba tion, artificial respiration was performed with room air in a tidal volume of 20 ml/kg at 18 breaths/min. The left chest was opened at the fifth intercostal space. The pericardium was cut to expose the heart. A micro-tip catheter pressure transducer (Millar, was in troduced through the left carotid artery into the left ventricle to measure the left ventricular pressure (LVP). The maximum rate of change in LVP ((+)dP/dt) was obtained with an electronic differentiator (Nihon Kohden. EQ 45764). A catheter was inserted into the left femoral artery and connected to a pressure transducer (Nihon Kohden, MPU-0.5) to measure the mean arterial pressure (MAP). The heart rate (HR) was measured with a cardiotachometer (Nihon Kohden, AT-601 G) triggered by LVP. Non-canulating probes of an electromagnetic flow meter (Nihon Kohden, MFV-1 200) were placed around the ascending aorta to measure the cardiac output (CO). The total peripheral resistance (TPR) (dyn-sec-cm-5) was calculated as:
All these variables were recorded on a thermal pen recorder (Nihon Kohden, WT-687) throughout the experiment. The animals were divided into three groups. The animals re ceived betaxolol (n=7), atenolol (n=7) and propranolol (n=7) in the first, second and third group, respectively. After a control peri od, the drugs were injected intravenously at 1 5 min intervals in cumulative doses of 3, 10, 30, 100, 300, 1000 and 3000 ;tg/kg through the cannula inserted into the left femoral vein. The administration interval of 15 min was chosen because all parameters measured in this experiment became stable 10 to 30 min after drug injection.
Effects on coronary circulation: Experi ments were performed on 21 mongrel dogs of either sex weighing 9-17.5 kg. The prepara tion was basically the same as that used by Narimatsu et al. (12) . The animals were anes thetized, and artificial respiration was per formed in the same way as that in the above experiment. The right chest was opened at the fourth and fifth intercostal spaces, and the fifth costa was removed. The pericardium was cut to expose the heart. After the animal was given sodium heparin at a dose of 500 units/ kg, i.v., a Morawitz cannula was introduced into the coronary sinus. The other end of the cannula was introduced into the right jugular vein to form a extracorporeal circuit made of rubber tubing. Coronary sinus outflow was returned to the main venous system through the circuit. A probe of the electromagnetic flow meter (Nihon Kohden, MFV-1200) was interposed in the circuit to measure the coro nary sinus outflow (CSF). Samples of coro nary sinus blood were obtained from the Morawitz cannula and those of arterial blood from the extracorporeal circuit in the right carotid artery. The oxygen content and pH of the blood samples were measured using a blood gas analyzer (Instrumental Laboratory, model 213). The coronary arteriovenous oxygen difference (A-V 02) was determined from arterial and coronary sinus blood sam ples obtained simultaneously.
After each ex periment, the heart was removed, rinsed, blotted and weighed. The myocardial oxygen consumption (MVO2) was calculated on the basis of the assumption that about 70% of the total coronary blood flowed out of the coro nary sinus. Two pairs of bipolar recording Pt electrodes were sutured on the sinus node area and on the right ventricular wall to ob tain atrial and ventricular bipolar electrograms, respectively. The atrio-ventricular conduction time (AVCT) was measured as the interval between the atrial and ventricular electrogram by an A-V interval meter (Data-Graph, HT 11) with an analysis pitch of 1 msec. MAP and H R were measured in the same way as that described for the above experiment. All the variables were recorded on a thermal pen re corder throughout the experiment.
The dogs were divided into three groups. The animals received betaxolol (n=7), aten olol (n=7) and propranolol (n=7) in the first, second and third group, respectively. The drugs were injected intravenously at 30 min intervals in cumulative doses of 3, 30, 300 and 3000 /tg/kg, through the cannula inserted into the left femoral vein. All the variables were measured 5 min before and 10 min after the drug injection.
Drugs: Drugs used were as follows: betaxolol hydrochloride (Synthelabo), aten olol (Sigma) and propranolol hydrochloride (Sigma). All drugs were dissolved in saline (0.9% NaCI). Betaxolol, atenolol and propranolol de creased CSF. When compared at the doses producing a 30% decrease in CSF, betaxolol was less potent than atenolol and propra nolol by 19 and 2.8 times, respectively. Betaxolol, atenolol and propranolol de creased A-V 02 and MVO2. When compared at the doses producing a 30% decrease in MVO2, betaxolol was almost equipotent with atenolol, but was 2.6 times less potent than propranolol. Betaxolol, atenolol and pro pranolol increased AVCT. The dose-response curve for the increase in AVCT with propra nolol was steeper than those with betaxolol and atenolol. The increase in AVCT with pro pranolol was greatest among the three drugs at the same dose.
Discussion
As expected from previous experiments using isolated cardiac muscle of guinea pig (5-7), betaxolol exerted a potent Q-adreno ceptor antagonistic effect in anesthetized dogs. In the present study, betaxolol, atenolol and propranolol produced dose-dependent decreases in HR, (+)dP/dt, CO and MAP. However, some of our findings indicated that betaxolol is qualitatively different from the other two drugs. The first finding is that betaxolol decreased TPR, whereas both atenolol and propranolol increased it. This decrease in TPR with betaxolol is of great interest because it is generally thought that most (3-adrenoceptor antagonists increase TPR as a result of compensatory sympathetic reflexes. Our present result is in agreement with the pre vious report by Powell that propranolol, when acutely administered to the anesthetized dog, increased TPR (13). The mechanism by which betaxolol decreases TPR is not clear at present. It is well-known that (3-adrenoceptor antagonists with either partial agonist ac tivity or a-adrenoceptor antagonist activity produce little or no increase in TPR (14, 15). It seems unlikely that partial agonist activity is responsible for the decrease in TPR with betaxolol because betaxolol has no such ac tivity (5). However, betaxolol, when injected intra-arterially, increased the femoral artery blood flow in anesthetized dogs, the potency of which was about one-thirds that of papa verine (16). These data suggest that betaxolol has a vasodilator property that may con tribute to the decrease in TPR. The extent to which the reflex increases TPR is proportional to the degree of the decrease in CO. There fore, there is another possibility that the de crease in CO with betaxolol was not sufficient to produce the reflex increase in TPR. How ever, such a possibility can be excluded be cause betaxolol at a dose of 3000 ug/kg and atenolol at a dose of 100 fig/kg, which pro duced nearly the same extent of decrease in CO, produced opposite changes in TPR. The increase in TPR with propranolol is probably due to the reflex caused by the decrease in CO and its 132-adrenoceptor blocking effect since (32-adrenoceptor blockade produces a con traction of the vascular smooth muscle, which leads to the increase in TPR. Increase in TPR with atenolol may be due to the reflex and no vasodilatory effect.
The second finding in the present experi ments is that betaxolol is much less potent than atenolol and propranolol in decreasing (+)dP/dt, although all the drugs were almost equipotent in decreasing HR. The reason why such a discrepancy occurs is not known. However, the less depressant effect on cardiac contractility was also observed in the canine ischemic heart model by Abe et al. (17) . This property may be advantageous for subjects with limited cardiac functional reserve.
The effectiveness of (3-adrenoceptor an tagonists in the treatment of exertional angina is attributable to a fall in myocardial oxygen consumption during exertion (18, 19) . In the present study, betaxolol decreased MV02 as did atenolol and propranolol. This suggests that betaxolol also has a beneficial effect on the ischemic myocardium. Recently, betaxolol was found to improve the myocardial acidosis due to coronary artery ligation in anesthetized dogs (17). Increase in AVCT with propranolol at the highest dose (3000 ,,cg/kg) was ap proximately two times those with betaxolol or atenolol. Although the 8-adrenoceptor an tagonistic effect of propranolol is thought to be the major mechanism of slowing A-V conduction (20), a direct depressant effect on atrioventricular transmission, including a membrane stabilizing action, may further in crease AVCT at higher doses (21-23). Pro pranolol can cause A-V dissociation and cardiac arrest in patients with preexisting partial heart block due to digitalis or other factors. In this respect, betaxolol and atenolol are less likely to induce A-V block than pro pranolol since betaxolol and atenolol were less potent in increasing AVCT.
In conclusion, betaxolol exhibited the profile of a cardioselective 13, -adrenoceptor antagonist, with decreasing effect on TPR. The decrease in TPR with betaxolol is likely to benefit the reduction in myocardial oxygen consumption as well as hypotensive effect. 
